SARS-CoV-2 Total Assay*: Securing your Community with Science and Scale
Vice President, Research and Development, Global Immunoassay Development
Siemens Healthineers | May 11, 2020
The COVID-19 pandemic has profoundly disrupted the world. Tools that can help address the full spectrum of challenges to help secure communities and combat this pandemic are needed. Testing large numbers of individuals for immune response/antibody status against the SARS-CoV-2 virus may help with re-opening society and assessing vaccine response (once available), as well as for managing the potential threat of additional infections.
In this video Jim Freeman discusses how design matters for SARS-CoV-2 antibody assays, especially the smart selection of the S1RBD antigen to detect antibodies that may block the virus entry into cells and how this strategy is aligned with vaccines in development.
*This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Product availability may vary by country and is subject to regulatory requirements.